In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599

Iizawa, Yuji; Nagai, Junko; Ishikawa, Tomoyasu; Hashiguchi, Shohei; Nakao, Megumi; Miyake, Akio; Okonogi, Kenji

doi:10.1007/s10156-004-0309-3

Cited by 79 publications

(60 citation statements)

References 19 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The MIC 90 for 100 strains of hVISA and VISA (19 VISA and 81 hVISA strains) was also 2 g per ml (range, 0.25 to 4 g per ml) (290). A few animal studies have shown ceftaroline to be useful for the treatment of MRSA infections, and in mice, ceftaroline was comparable or superior to vancomycin, linezolid, teicoplanin, and arbekacin (136). In a rabbit endocarditis model, ceftaroline was highly bactericidal against MRSA and hVISA compared with linezolid and vancomycin (139).…”

Section: Potentially Active Antimicrobials In Developmentmentioning

confidence: 99%

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

et al. 2010

View full text Add to dashboard Cite

SUMMARY The emergence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) over the past decade has provided a challenge to diagnostic microbiologists to detect these strains, clinicians treating patients with infections due to these strains, and researchers attempting to understand the resistance mechanisms. Recent data show that these strains have been detected globally and in many cases are associated with glycopeptide treatment failure; however, more rigorous clinical studies are required to clearly define the contribution of hVISA to glycopeptide treatment outcomes. It is now becoming clear that sequential point mutations in key global regulatory genes contribute to the hVISA and VISA phenotypes, which are associated predominately with cell wall thickening and restricted vancomycin access to its site of activity in the division septum; however, the phenotypic features of these strains can vary because the mutations leading to resistance can vary. Interestingly, changes in the staphylococcal surface and expression of agr are likely to impact host-pathogen interactions in hVISA and VISA infections. Given the subtleties of vancomycin susceptibility testing against S. aureus, it is imperative that diagnostic laboratories use well-standardized methods and have a framework for detecting reduced vancomycin susceptibility in S. aureus.

show abstract

Section: Potentially Active Antimicrobials In Developmentmentioning

confidence: 99%

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Ceftaroline has broad-spectrum activity that encompasses many community-and hospital-acquired pathogens, including MRSA, multidrug-resistant S. pneumoniae (MDRSP), and common (non-ESBL-producing) gram-negative bacteria (11,15,23). This study evaluated the in vitro activity of ceftaroline against a collection of recent clinical isolates from the United States, including bacteria exhibiting resistance to currently available antimicrobial agents.…”

mentioning

confidence: 99%

In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

Ge¹,

Biek²,

Talbot³

et al. 2008

Antimicrob Agents Chemother

124

View full text Add to dashboard Cite

This study evaluated the in vitro activity of ceftaroline, a novel cephalosporin with broad-spectrum activity against gram-negative and -positive pathogens, against 4,151 recent clinical isolates collected in the United States. Ceftaroline was very potent against bacteria found in community-and hospital-acquired infections, including methicillin-resistant Staphylococcus aureus, multidrug-resistant Streptococcus pneumoniae, and common Enterobacteriaceae spp.

show abstract

“…Finally, two 5 th generation cephalosporin prodrugs (ceftaroline fosamil and ceftobiprole medocaril) have been found to possess anti-MRSA activities. Ceftaroline has been shown to produce similar clinical cure rates as vancomycin in complicated skin and skin structure infections (Iizawa, Nagai et al 2004;Ge, Biek et al 2008), whereas ceftobiprole was found to show similar efficacy as vancomycin in suspected gram positive infections, diabetic foot and mixed bacterial complicated skin and skin structure infectons (Noel, Bush et al 2008 a;Noel, Strauss et al 2008;Noel, Strauss et al 2008 b). In summary, several newer antibiotics have been shown to provide a potential equally effective but less nephrotoxic alternative to vancomycin for deep-seated MRSA infections.…”

Section: Discussionmentioning

confidence: 99%

Vancomycin-Induced Nephrotoxicity

Ahmad¹,

Abu-Romeh²,

Rousan³

et al. 2012

Basic Nephrology and Acute Kidney Injury

View full text Add to dashboard Cite

In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599

Cited by 79 publications

References 19 publications

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

Reduced Vancomycin Susceptibility inStaphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications

In Vitro Profiling of Ceftaroline against a Collection of Recent Bacterial Clinical Isolates from across the United States

Vancomycin-Induced Nephrotoxicity

Contact Info

Product

Resources

About